EBIT: Income before interest and taxes.
CNS Pharmaceuticals, Inc. (CNSP) had EBIT of $-2.41M for the most recently reported fiscal quarter, ending 2025-06-30.
Income Statement Financials | |
-- |
|
$-2.38M |
|
-- |
|
-- |
|
$2.41M |
|
$-2.41M |
|
$0.03M |
|
$-2.38M |
|
$-2.38M |
|
$-2.38M |
|
$-2.38M |
|
$-2.38M |
|
$-2.38M |
|
EBIT |
$-2.41M |
$-2.41M |
|
0.37M |
|
0.37M |
|
$-6.42 |
|
$-6.42 |
|
Balance Sheet Financials | |
$14.14M |
|
$0.00M |
|
$0.37M |
|
$14.51M |
|
$1.38M |
|
-- |
|
-- |
|
$1.38M |
|
$13.12M |
|
$13.12M |
|
$13.12M |
|
0.50M |
|
Cash Flow Statement Financials | |
$-8.59M |
|
-- |
|
$14.25M |
|
$6.46M |
|
$12.13M |
|
$5.67M |
|
$0.08M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
10.22 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.59M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-18.09% |
|
-18.09% |
|
-16.37% |
|
-18.09% |
|
$26.04 |
|
$-23.20 |
|
$-23.20 |